A Novel Pathogenic DNA Variation in the OCRL1 Gene in Lowe Syndrome by Şimşek, Enver et al.
J Clin Res Ped Endo 2011;3(1):29-31
DOI: 10.4274/jcrpe.v3i1.06
Enver ﬁimﬂek1, Tülay ﬁimﬂek2, Y›ld›z Dallar3, Önder Can3, Patrick J. Willems4
1Division of Pediatric Endocrinology, Department of Pediatrics, School of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey
2Department of Glaucoma, Ulucanlar Eye Research and Training Hospital, Ankara, Turkey
3Department of Pediatrics, Ankara Research and Training Hospital, Ankara, Turkey
4GENDIA Genetic Diagnostic Network, B-2020 Antwerp, Belgium
Address for Correspondence
Enver ﬁimsek, Division of Pediatric Endocrinology, Department of Pediatrics, Eskisehir Osmangazi University, School of Medicine, Eskiﬂehir, Turkey
Gsm: +90 505 496 23 02 E-mail: enversimsek06@hotmail.com
©Journal of Clinical Research in Pediatric Endocrinology, Published by Galenos Publishing.
A Novel Pathogenic DNA Variation in the OCRL1 




The oculocerebrorenal syndrome of Lowe (OCRL) was first
recognized as a distinct disease in 1952 by Lowe et al (1). The
diagnostic triad of OCRL or Lowe syndrome includes eye
anomalies (congenital cataracts, infantile glaucoma) resulting in
impaired vision, neurological deficits (infantile hypotonia with
subsequent mental impairment, absent deep tendon 
reflexes), and renal tubular dysfunction of the Fanconi type
with glomerulosclerosis resulting in progressive chronic renal
failure and end-stage renal disease (2,3). The disease is caused
by pathogenic DNA variations in the OCRL1 gene on 
chromosome Xq26.1, which encodes the phosphatidylinositol
polyphosphate 5-phosphatase protein. This protein is primarily
located in the trans-Golgi network, on endosomes, and at the
endocytic clathrin-coated pits. It regulates the concentration of 
intracellular phosphatidylinositol (4,5) bisphosphate, which is a
membrane phospholipid known to regulate many intracellular
processes. More than 100 pathogenic DNA variations leading
to Lowe syndrome have been described, of which more than
90% are located in 2 hot spots (exons 10-18 and 19-23) in the
OCRL1 gene. 
We report here a novel pathogenic DNA variation in exon
15 of the OCRL1 gene in a patient with Lowe syndrome.
Case Report
A 24-month-old boy was referred to our hospital with
delayed motor milestones, hypotonia, involuntary purposeless
movements of hands and feet, congenital cataract, severe
feeding difficulties, and failure to thrive. His past medical 
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history revealed that he was born at term after a normal 
pregnancy period. He is the first child of a non-
consanguineous marriage, and detailed pedigree 
analysis did not show any positive family history. Birth 
weight was 3600 g. Length at birth was 51 cm and head 
circumference 35.5 cm. The boy was on breastfeeding for
only two months, and thereafter, on formula feeding for 8
months. At 24 months of age, he could not crawl or walk and
could not sit without support. He was hospitalized several
times to investigate the cause of his failure to thrive 
and recurrent respiratory tract infections, but there was no
specific diagnosis to explain his symptoms and signs. Physical
examination at age 24 months revealed a  body weight of
7350 g (-5.1 SDS). Length was 71 cm (-5.1 SDS) and head 
circumference 45 cm (-3.9 SDS). He had deep-set small eyes,
frontal bossing, a flat occiput, parietal prominence, bilateral
congenital cataract, cryptorchidism on the left side, joint 
hypermobility, decreased muscle tone, and hyporeflexia
(Figure 1). The laboratory investigations are presented in Table 1.
Serum thyroxine (T4) and free thyroxine (fT4) levels were low,
while serum thyrotropin (TSH) level was in normal ranges.
Radiographs of the wrists and knees demonstrated 
metaphyseal flaring, which is a characteristic sign of rickets.
Renal ultrasonography showed evidence of nephrocalcinosis.
The diagnosis of OCRL was based on the findings of 
congenital cataract, hypotonia, delayed motor developmental
milestones, and renal Fanconi syndrome. Ophthalmological
examination revealed bilateral congenital cataract and normal
intraocular pressure. Cataract surgery was performed within
the first month of hospital admission. For the management of
his renal tubular acidosis, sodium citrate and potassium 
citrate (Polycitra) were administered. Neutral phosphate and
calcitriol were administered to manage hypophosphatemic
rickets. Following replacement therapy, serum TSH level was
3.7 μIU/mL and fT4 increased to 1.42 ng/dL.
To confirm the clinical diagnosis of Lowe syndrome, 
the  OCRL1 gene was analyzed. Genomic DNA from the
patient was used for polymerase chain reaction (PCR)
amplification followed by direct sequencing of the entire 
coding region (exons 1-24) of the OCRL1 gene, including all
intron-exon boundaries. A hemizygous c.1528C>T DNA 
variation was identified in exon 15 of the OCRL1 gene. This
DNA variation alters a  glutamine into a premature stop codon
on position 510 (p.Gln510X). The familial c.1528C>T mutation
was also present in heterozygous state in the 
mother of the patient. Unfortunately, the mother did not 
undergo an ophthalmologic examination.
Discussion 
Patients with Lowe syndrome typically present in infancy
with cataracts, progressive growth failure, hypotonia, and
Fanconi syndrome, as seen in the present case. Because of
the low prevalence of this disorder (1:200 000 -1:500 000
births)  (4), clinicians may not be familiar with it. 
Lowe syndrome should be differentiated from other disorders
associated with congenital cataract, hypotonia, proximal renal
dysfunction and developmental delays, including congenital
infections (such as TORCH infections), Zellweger syndrome,
galactosemia, cystinosis, hereditary fructose intolerance and
tyrosinemia. Clinical and laboratory studies eventually lead to
the correct clinical diagnosis, which can be confirmed 
by molecular studies of the OCRL1 gene located on 
chromosome Xq24-26 (5,6,7). To date, more than 100 
pathogenic DNA variations have been reported in the OCRL1
gene  (8). We present here an additional pathogenic DNA 
variation in the OCRL1 gene. The c.1528C>T mutation in 
exon 15 of the OCRL1 gene is a nonsense variation altering a
glutamine into a premature stop codon on position 510
(p.Gln510X). This pathogenic DNA variation is predicted to
result in a truncated OCRL1 protein or diminished OCRL1
mRNA due to mRNA decay. The c.1528C>T mutation is a
novel pathogenic DNA variation not previously described in
other patients with Lowe syndrome.
Table 1. The laboratory results  in the patient 
Results Normal ranges
Hemoglobin (g/dL) 9.9 11.5-14.5
Plasma glucose (mg/dL) 97 70-100
BUN (mg/dL) 18 < 20
Creatinine (mg/dL) 0.4 0.2-0.4
Sodium (mEq/L) 132 135-145
Potassium (mEq/L) 2.7 3.5-4.5
Chloride (mEq/L) 114 95-105
Calcium (total, mg/dL) 8.9 8.8-10.8
Phosphorus (mg/dL)  1.8 3.8-6.5
Phosphatase alkaline (U/L) 660 145-420
Blood pH 7.25 7.35-7.45
Blood HCO3 (mEq/L) 17.5 24-28
TSH (μIU/mL) 2.5 0.5-4.5
Thyroxin, total (mg/dL) 6.1 6.8-13.5
Thyroxin, free (ng/dL) 0.59 0.9-2.6
Vitamin D,25-OH (ng/mL) 54.5 7.4-53.3
Urine density 1008 1001-1025
Urine pH 6.5 4-8
Urine glucose (quantitative) (-) (-)
Urinary aminoacid profile generalized aminoaciduria(-)
Ca/Cr ratio in spot urine sample 1.2 < 0.5
TmP (%) 65 >90
BUN, blood urea nitrogen; TSH, thyrotropin
TmP; The maximum rate of tubular phosphate reabsorption Figure 1. The clinical characteristics of the patient31
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Proximal tubulopathy and OCRL1 gene mutation are also
associated with Dent’s disease, a rare X-linked recessive
inherited condition that affects the proximal renal tubules (9).
The disorder has two different genetic backgrounds. Dent’s
disease 1 is caused by mutations in the renal chloride 
channel CLCN5 that encodes a kidney-specific voltage gated
chloride channel (10). Dent’s disease 2 is associated with
OCRL1 gene mutation (11). Dent’s disease manifests itself
through extreme thirst combined with dehydration, which
leads to frequent urination, tubular proteinuria, hypercalciuria,
nephrocalcinosis (kidney stones), aminoaciduria, phosphaturia,
glycosuria, and impaired urinary acidification. However, this
disorder does not present with congenital cataract 
and severe hypotonia. Cataracts are a hallmark of Lowe 
syndrome and are always present at birth. Congenital cataract,
hypotonia, and the characteristic findings of proximal 
tubulopathy revealed the diagnosis of Lowe  syndrome in our
patient, and the genetic analysis confirmed the diagnosis.
Lowe syndrome cells have an elevated concentration of 
phosphatidylinositol 4,5-bisphosphate, the substrate for the
OCRL1 protein (12). The presence of a reproducible cellular
abnormality of the actin cytoskeleton in fibroblasts from
patients with Lowe syndrome has been demonstrated (13).
Actin polymerization plays a major role in the formation, 
maintenance, and proper function of adherens and tight 
junctions that have been shown to be crucial for the function
of renal proximal tubule and for the lens differentiation.
The initial thyroid function tests in our case could be
explained either by a state of  central hypothyroidism or by the
development  of euthyroid sick syndrome, a condition often
encountered in patients in intensive care units and thought to
be due to starvation or critical illness (14). Our patient had renal
tubular acidosis and chronic protein energy malnutrition, 
which we initially tried to correct. He was followed-up at three-
monthly intervals. At the second follow-up visit, six month
after initiation of replacement therapy, his mother reported
that he had head control and had started crawling.
Biochemical analysis revealed blood gases within normal
ranges. Thyroid function tests had also improved following
replacement therapy. This progress indicates that the initial
thyroid dysfunction could be due to euthyroid sick syndrome. 
Genetic counselling should be done for carrier detection
and prenatal testing. Molecular analysis of the OCRL1 gene is
a more specific way to diagnose female carriers if the 
mutation in the proband is known (4). Genetic mutations
should be documented first in the proband. As many as 94%
of female carriers may be detected during ophthalmologic
examination by slit-lamp biomicroscopy and the typical 
findings are multiple punctuate lenticular opacities or a 
single dense posterior cataract (15,16). However, even if the
mother has normal ocular findings, mutation analysis should
still be done due to the fact that though rarely, some women
are nonpenetrant carriers and do not have the characteristic
eye manifestations. Unfortunately, ophthalmic examination
was not performed on the mother of the present case. The
OCRL1 gene mutation analysis revealed that the familial
c.1528C>T variation was also present in heterozygous state in
the mother. If the mother of the proband is a carrier, as in this
study, each male offspring has a 50% chance of 
being affected, while each female has a 50% chance of being
a carrier. On the other hand, if the mother does not have the
characteristic ocular findings and no OCRL1 mutations 
are found, then the mutation may be new and has a low 
recurrence risk (16). If genetic mutation is documented in the
proband, prenatal testing is also possible for at-risk pregnancies,
using either molecular analysis or biochemical testing (17).
In conclusion, Lowe syndrome should be suspected in
males with congenital cataracts, developmental anomalies,
and renal tubular dysfunction of the Fanconi type. The finding of
a pathogenic DNA variation in OCRL1 gene can confirm the 
diagnosis. Early diagnosis and treatment of metabolic
disturbances may delay the morbidity and mortality in this 
syndrome. 
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